Mr. Steinberg stated, “Pacira remains one of the rare ‘hyper growth’ stories in life sciences — with stellar execution leading to Exparel annualizing at $180M (just 1.6 percent share) after nine quarters.”
Pacira Pharmaceuticals’ shares closed yesterday at $101.85.
